BCDA (BioCardia, Inc) רווחיות מכירות לפי רווח גולמי

The financial position of BioCardia, Inc. (BCDA) relies on raised capital, as commercial products have not yet entered the market. The relative gross margin reflects profitability trends, where 0.00 shows the current value of the metric. Risk mitigation is achieved through the testing of cell systems across various cardiological profiles, although the cost of cryogenic air delivery for biomaterials significantly increases the company's operating expenses.
פילוחי מדדים פיננסיים ומדדי שוק עבור BioCardia, Inc. (BCDA)

For BioCardia, Inc. (BCDA), gross margin serves as an indicator of efficiency in covering direct costs associated with cell therapy development. This metric measures the portion of revenue remaining after deducting the cost of goods sold, allowing for an assessment of the fundamental profitability of each product unit. An analysis of gross margin stability confirms that the issuer's current financial performance depends entirely on clinical trial outcomes and future market approval.